1
ALL1
Aurisco PharmaceuticalYear
1
ALL1
2023DEALS // DEV.
1
ALL1
DevelopmentsCountry
1
ALL1
CHINA1
ALL1
InapplicableTherapeutic Area
1
ALL1
Obstetrics/Gynecology (Women’s Health)Study Phase
1
ALL1
Approved FDFDeal Type
1
ALL1
InapplicableProduct Type
1
ALL1
HormoneDosage Form
1
ALL1
Oral TabletLead Product
1
ALL1
DydrogesteroneTarget
1
ALL1
Progesterone receptorLead Product(s) : Dydrogesterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aurisco Gets Auxiton (Dydrogesterone) as First Generic Approval in China
Details : Auxiton (dydrogesterone) is a potent orally active progesterone receptor agonist that is used for the treatment of disorders such as premenstrual syndrome, cycle irregularity, endometriosis, threatened miscarriage, and habitual miscarriage, and for postm...
Product Name : Auxiton
Product Type : Hormone
Upfront Cash : Inapplicable
June 27, 2023
Lead Product(s) : Dydrogesterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable